Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
97% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. ATRS: No Debt )
ATRS' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.67
ATRS's Equity to Asset is ranked higher than
78% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ATRS: 0.67 )
ATRS' s 10-Year Equity to Asset Range
Min: -4.09   Max: 0.95
Current: 0.67

-4.09
0.95
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
88% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. ATRS: No Debt )
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 4.18
M-Score: -3.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -135.78
ATRS's Operating margin (%) is ranked lower than
52% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. ATRS: -135.78 )
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11   Max: -26.96
Current: -135.78

-1709.11
-26.96
Net-margin (%) -134.45
ATRS's Net-margin (%) is ranked lower than
51% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. ATRS: -134.45 )
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74   Max: -26.66
Current: -134.45

-1728.74
-26.66
ROE (%) -48.87
ATRS's ROE (%) is ranked higher than
53% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. ATRS: -48.87 )
ATRS' s 10-Year ROE (%) Range
Min: -6822.87   Max: -19.42
Current: -48.87

-6822.87
-19.42
ROA (%) -36.63
ATRS's ROA (%) is ranked higher than
52% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. ATRS: -36.63 )
ATRS' s 10-Year ROA (%) Range
Min: -530.86   Max: -15.37
Current: -36.63

-530.86
-15.37
ROC (Joel Greenblatt) (%) -398.93
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. ATRS: -398.93 )
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2300.72   Max: -395.82
Current: -398.93

-2300.72
-395.82
Revenue Growth (3Y)(%) 2.20
ATRS's Revenue Growth (3Y)(%) is ranked higher than
69% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ATRS: 2.20 )
ATRS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.4   Max: 89.8
Current: 2.2

-63.4
89.8
EBITDA Growth (3Y)(%) 31.70
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. ATRS: 31.70 )
ATRS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9   Max: 31.7
Current: 31.7

-41.9
31.7
EPS Growth (3Y)(%) 31.70
ATRS's EPS Growth (3Y)(%) is ranked higher than
90% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ATRS: 31.70 )
ATRS' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1   Max: 31.7
Current: 31.7

-58.1
31.7
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ATRS Guru Trades in Q4 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q1 2014

ATRS Guru Trades in Q1 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q2 2014

ATRS Guru Trades in Q2 2014

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q3 2014

ATRS Guru Trades in Q3 2014

Jim Simons 145,728 sh (New)
Jean-Marie Eveillard 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3 $ 2.63-14%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.74
ATRS's P/B is ranked higher than
58% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. ATRS: 6.74 )
ATRS' s 10-Year P/B Range
Min: 2.26   Max: 77.5
Current: 6.74

2.26
77.5
P/S 14.61
ATRS's P/S is ranked higher than
50% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. ATRS: 14.61 )
ATRS' s 10-Year P/S Range
Min: 3.56   Max: 36
Current: 14.61

3.56
36
EV-to-EBIT -9.62
ATRS's EV-to-EBIT is ranked higher than
60% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. ATRS: -9.62 )
ATRS' s 10-Year EV-to-EBIT Range
Min: -121.9   Max: -1
Current: -9.62

-121.9
-1
Current Ratio 2.92
ATRS's Current Ratio is ranked higher than
77% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. ATRS: 2.92 )
ATRS' s 10-Year Current Ratio Range
Min: 0.11   Max: 17.17
Current: 2.92

0.11
17.17
Quick Ratio 2.53
ATRS's Quick Ratio is ranked higher than
79% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. ATRS: 2.53 )
ATRS' s 10-Year Quick Ratio Range
Min: 0.09   Max: 16.5
Current: 2.53

0.09
16.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.62
ATRS's Price/Net Cash is ranked higher than
90% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ATRS: 14.62 )
ATRS' s 10-Year Price/Net Cash Range
Min: 1.18   Max: 108
Current: 14.62

1.18
108
Price/Net Current Asset Value 11.96
ATRS's Price/Net Current Asset Value is ranked higher than
86% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ATRS: 11.96 )
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 1.01   Max: 108
Current: 11.96

1.01
108
Price/Tangible Book 7.30
ATRS's Price/Tangible Book is ranked higher than
68% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. ATRS: 7.30 )
ATRS' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 44.5
Current: 7.3

0.62
44.5
Price/Median PS Value 1.14
ATRS's Price/Median PS Value is ranked higher than
75% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. ATRS: 1.14 )
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.49
Current: 1.14

0.08
2.49
Earnings Yield (Greenblatt) -10.40
ATRS's Earnings Yield (Greenblatt) is ranked higher than
54% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. ATRS: -10.40 )
ATRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -10.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany,
Antares Pharma, Inc., formerly known as Medi-Ject Corporation, or Medi-Ject, was incorporated on February 1979. The Company is a specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceutical products and technologies. It has a number of partnerships with pharmaceutical companies as well as internal product development programs. It develops both subcutaneous and intramuscular injection technology systems. It launched OTREXUP injection on January 2014, is a subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. It is indicated for adults with severe active rheumatoid arthritis or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company has international marketing rights for its OTREXUP. It is also developing Vibex QS for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency. The Company has licensed its reusable needle-free injection device for use with human growth hormone to Teva Pharmaceutical Industries, Ltd., Ferring Pharmaceuticals BV and JCR Pharmaceuticals Co., Ltd., with Teva and Ferring being two of the Company's primary customers. The Company's needle-free injection device is marketed by Teva as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH marketed in the U.S. The Company's needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. It has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. It also has a portfolio of gel-based products such as Gelnique, a topical oxybutynin gel product for the treatment of overactive bladder. Gelnique is marketed by Actavis in the U.S. In South Korea, Gelnique is marketed by Daewoong Pharmaceuticals. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, among others.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
Multiple FDA-Cleared Devices Give This Company Extraordinary Upside Dec 03 2014
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Dec 01 2014
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events Nov 21 2014
Antares Pharma Appoints James E Fickenscher, Senior Vice President, Chief Financial Officer Nov 18 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Nov 18 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer Nov 18 2014
ANTARES PHARMA, INC. Financials Nov 15 2014
10-Q for Antares Pharma, Inc. Nov 08 2014
Antares Pharma posts 3Q loss Nov 06 2014
Antares Pharma posts 3Q loss Nov 06 2014
Q3 2014 Antares Pharma Inc Earnings Release - Before Market Open Nov 06 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Nov 06 2014
Antares Pharma Reports Third Quarter 2014 Operating and Financial Results Nov 06 2014
Antares Pharma Announces Last Patient Enrolled in Phase 3 Quickshot Study Evaluating... Nov 03 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 03 2014
Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK